Complaint Counsel's cross-motion to the extent that it seeks to limit respondents' experts'

ability to present their opinions in response to Dr. Levy's opinion in this regard.

With respect to the question of Dr. Pitt's testimony, Schering will soon file a motion in

limine that will seek to exclude some of the testimony Dr. Pitt intends to present at the hearing

on the subject of FDA approvability. Schering will show that, under clearly relevant case law,

certain portions of his testimony are subject to exclusion. Because the issues that will be raised

in Schering's motion in limine are closely related to those raised by Upsher's motion and

Complaint Counsel's cross-motion, Schering respectfully suggests that the Court may wish to

defer resolution of all motions relating to Dr. Pitt until breifing on Schering's motion in limine is

completed.

Respectfully submitted,

John W. Nields, Jr.

Marc G. Schildkraut

Laura S. Shores

Charles A. Loughlin

HOWREY SIMON ARNOLD & WHITE LLP

1299 Pennsylvania Ave., N.W.

Washington, D.C. 20004

(202) 783-0800

Attorneys for Respondent

Schering-Plough Corporation

Dated: December 20, 2001

2

## **CERTIFICATE OF SERVICE**

I hereby certify that this 20th day of December, 2001, I caused an original, one paper copy and an electronic copy of the foregoing Respondent's Response to Complaint Counsel's Cross-Motion In Limine to Exclude Expert Testimony on FDA Approval of Niacor

## CERTIFICATION

I hereby certify that this 20th day of December, 2002, I caused an electronic copy of Respondent's
Response to Complaint Counsel's Cross-Motion In Limine to Exclude Expert Testimony on FDA
Approval of Niacor-SR to be filed with the Secretary of the Commission. I further certify that these
are true and correct copies of the paper original and that a paper copy with an original signature is
being filed with the Secretary of the Commission.

Erik T. Koons